Combo Drug Effective for T2DM Prevention in Patients with Prediabetes, Metabolic Syndrome
the MPR take:
Phentermine and topiramate extended release ((PHEN/TPM ER) with lifestyle modification has shown to reduce the progression to type 2 diabetes in overweight/obese patients with prediabetes and/or metabolic syndrome. According to research in Diabetes Care, 475 overweight/obese subjects with two or more comorbidities including prediabetes and/or metabolic syndrome received either PHEN 7.5mg/TPM ER 46mg, PHEN 15mg/TPM ER 92mg, or placebo, plus lifestyle modification for 108 weeks. While all groups experienced weight loss, patients in the PHEN 7.5mg/TPM ER 46mg and PHEN 15mg/TPM ER 92mg groups had 70.5% and 78.7% reductions in the annualized incidence rates of type 2 diabetes, respectively vs. placebo. Significant improvements in cardiometabolic parameters were also seen in the PHEN/TPM ER groups.
OBJECTIVE: To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline. RESEARCH DESIGN AND METHODS ...
READ FULL ARTICLE From care.diabetesjournals.org